At the Stem Cells Transplant Institute in Costa Rica, we offer mesenchymal stem cell (MSC) therapy for autism (ASD) to support neurological function and improve quality of life.
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by differences in social communication, sensory processing, and behavioral patterns. Each individual with autism has a unique profile of strengths and challenges.
Current research suggests that autism involves neuroinflammation, immune dysregulation, and differences in neural connectivity. These insights have opened new pathways for therapeutic interventions, including regenerative medicine approaches.
At the Stem Cells Transplant Institute in Costa Rica, we offer personalized mesenchymal stem cell (MSC) therapy programs for individuals with Autism Spectrum Disorder (ASD).
Our approach combines science, safety, and compassionate care to help address biological factors that may contribute to autism, such as inflammation, immune dysregulation, and neural connectivity imbalance.
CDC, Autism and Developmental Disabilities Monitoring Network, 2023
Stem cell therapy for Autism (ASD) at Stem Cells Transplant Institute is delivered in San José, Costa Rica, within a certified medical facility operating under structured clinical protocols and physician supervision.
Families from the United States, Canada, and Europe travel to Costa Rica to access MSC therapy programs that remain largely unavailable in their home countries at a significantly lower cost than comparable private programs in North America.
There are direct flights from major U.S. and Canadian cities to San José that typically last 3 to 5 hours. At our institute, most on-site protocols are completed within 3 to 5 days. These are practical logistics important when traveling with a child with specific routine and sensory needs.
Finally, all autism treatment programs begin with a medical screening and case review. Each therapy protocol is adjusted to your child’s diagnosis, medical history, and clinical evaluation.
Emerging clinical research suggests that mesenchymal stem cells may help to support the body’s own healing and regulatory processes.
Preclinical and early clinical studies indicate that mesenchymal stem cells (MSCs) can help modulate inflammation, balance immune responses, and promote healthier neural activity.
(Evidence remains preliminary, and ongoing controlled clinical trials are required to confirm the magnitude and consistency of these effects.
MSCs release signaling molecules(cytokines and growth factors) that can help reduce inflammatory processes in the brain.
Lower inflammation may allow neuron to function more effectively
(Source: Frontiers in Pediatrics, 2022)
MSCs may help “reset” immune activity toward a more regulated state, potentially working in a healthier way.
This may help reduce chronic inflammation and improve overall well-being.
(Source: World Journal of Methodology, 2021)
MSCs naturally release trophic factors (protective proteins) that support neural survival and synaptic connectivity.This may strengthen areas of the brain involved in communication, learning, and behavior.
(Source: Frontiers in Cell & Developmental Biology, 2022)
Brain scans from clinical studies have suggested that some patients may experience enhanced communication between brain regions following stem cell therapy, which could be be associated with improved attention, calmness, or stronger social responses.
(Source: Stem Cells Translational Medicine, 2019)
Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:
*These percentages summarizes ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy in autism remains preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proof of efficacy.
Published studies and patient-reported outcomes suggest that improvements after mesenchymal stem cell (MSC) therapy for autism may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly
*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy in autism remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.
When performed in a controlled medical environment under physician supervision, MSC therapy has shown a generally favorable safety profile. Temporary fatigue, mild fever, or slightly discomfort at the infusion site may occur.
No. Autism is a complex neurodevelopmental condition. Stem cell therapy is not a cure but may help improve certain biological and functional parameters and overall quality of life.
Most patients undergo one protocol (single or multiple infusions) with follow-up evaluations at 3 and 6 months.
The route of administration is determined by the treating physician and may include intravenous (IV) or, in selected research-based cases, intrathecal (IT) infusion under strict sterile and anesthetic conditions.
The choice of route depends on individual evaluation, safety considerations, and clinical rationale.
We use umbilical-cord-derived mesenchymal stem cells (UC-MSCs) obtained from ethically screened and tested donors, processed in an certified lab under Costa Rican health regulations.
Some improvements may appear within 1–3 months, with continued changes up to 12 months post-treatment.
Responses vary between individuals, and no specific outcome can be guaranteed.
Most reported side effects are mild and temporary (e.g., fatigue, low-grade fever, or local soreness).
Less common but possible risks include:
If intrathecal administration is performed, additional specific risks include:
All procedures are conducted under continuous medical supervision with emergency support available on-site.
Stem cell therapy for autism in Costa Rica typically costs 50% to 70% less than in the United States. Exact pricing depends on the treatment plan, but patients can expect significant savings while receiving personalized regenerative care.
Systematic review and meta-analysis reporting improvements in autism symptoms and an overall favorable safety profile for stem cell therapy.
View published study
Clinical review suggesting MSC therapy may help regulate immune dysfunction and support behavioral improvements in ASD.
View published study
Scientific analysis supporting MSCs as a promising approach to address neuroinflammation and immune imbalance in autism.
View published study
Systematic review of clinical trials reporting positive therapeutic trends and safety of cell therapies in ASD.
View published study
San José, Costa Rica
info@stemcellstransplantinstitute.com
+1 888 785-4170
